Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Cstl source : Www.biospace.com save search
Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024
Published: 2024-04-11 (Crawled : 12:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: 0.63%
H: 0.82%
C: -0.14%
first conference financial results
Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year
Published: 2024-04-10 (Crawled : 12:00) - biospace.com/
XYF | $3.78 0.0% 5.6K
|
Finance
|
| O: -2.11%
H: 2.96%
C: 2.15%
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: -1.76%
H: 0.0%
C: 0.0%
year for financial
Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
Published: 2024-04-02 (Crawled : 12:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: -0.46%
H: 2.72%
C: 2.26%
conference
Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year
Published: 2024-03-25 (Crawled : 00:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: -0.74%
H: 5.82%
C: 3.48%
award year workplaces usa
Vivani Medical Appoints Daniel Bradbury to its Board of Directors
Published: 2024-03-06 (Crawled : 15:30) - biospace.com/
VANI | $1.7 -5.82% -6.18% 190K
|
Manufacturing
|
| O: 4.65%
H: 4.44%
C: -1.78%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 1.0%
H: 2.81%
C: 1.99%
EQ | $1.63 -5.78% -6.13% 100K
|
Health Technology
|
| O: -0.45%
H: 7.35%
C: 1.35%
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: 1.52%
H: 1.32%
C: -5.25%
medical
Castle Biosciences to Release Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call on Wednesday, Feb. 28, 2024
Published: 2024-02-07 (Crawled : 13:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: 0.79%
H: 1.29%
C: -2.98%
conference financial results
Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Selected Among the Top 25 Women Leaders in Biotechnology by The Healthcare Technology Report
Published: 2024-01-09 (Crawled : 14:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: -1.74%
H: 2.72%
C: -2.47%
report women leaders technology
Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2023 Results
Published: 2024-01-08 (Crawled : 08:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: 0.81%
H: 3.68%
C: 3.31%
results
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 20, 2023
Published: 2023-12-20 (Crawled : 13:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: -0.57%
H: 2.49%
C: -2.29%
nasdaq grants
Castle Biosciences Reports Third Quarter 2023 Results
Published: 2023-11-02 (Crawled : 00:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: 2.8%
H: 5.82%
C: 3.16%
results
Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors
Published: 2023-10-23 (Crawled : 13:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.19%
H: 0.66%
C: -0.62%
ICPT | $19.0 -0.05% 4M
|
Health Technology
|
| O: -0.16%
H: 0.0%
C: 0.0%
EQ | $1.63 -5.78% -6.13% 100K
|
Health Technology
|
| O: 1.16%
H: 3.28%
C: -2.68%
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: 0.0%
H: 1.87%
C: 0.0%
Castle Biosciences to Release Third Quarter 2023 Financial Results and Host Conference Call on Thursday, Nov. 2
Published: 2023-10-19 (Crawled : 12:30) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: -0.46%
H: 0.23%
C: -1.23%
conference financial results
New Data Highlights Clinical Utility and Performance of Castle Biosciences’ Dermatologic Test Portfolio at the 2023 Fall Clinical Dermatology Conference®
Published: 2023-10-18 (Crawled : 23:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: -0.88%
H: 1.02%
C: -3.2%
conference test
DecisionDx®-Melanoma Outperforms Memorial Sloan Kettering Cancer Center (MSKCC) Nomogram in Predicting Sentinel Lymph Node Positivity in Patients with Cutaneous Melanoma
Published: 2023-10-05 (Crawled : 13:30) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: -0.26%
H: 1.37%
C: -3.32%
decisiondx melanoma cancer sentinel
Castle Biosciences Presents New Data at ASTRO 2023 Highlighting Risk-Stratification Performance of DecisionDx®-SCC in Patients with Cutaneous Squamous Cell Carcinoma Eligible for Adjuvant Radiation Therapy
Published: 2023-10-03 (Crawled : 13:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: -0.97%
H: 0.0%
C: -3.81%
decisiondx cell therapy
Castle Biosciences Shares New Data Demonstrating Ability of TissueCypher® Test Results to Inform Clinical Decision-Making in Patients with Non-Dysplastic Barrett’s Esophagus
Published: 2023-10-02 (Crawled : 17:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: -0.3%
H: 0.0%
C: -2.43%
tissuecypher test results
Castle Biosciences, Leading Skin Cancer Expert, Darrell Rigel, M.D., M.S., and IMPACT Melanoma Board Member to Ring Nasdaq Closing Bell on Sept. 27, 2023, to Raise Awareness of Melanoma
Published: 2023-09-25 (Crawled : 12:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: 0.85%
H: 0.0%
C: -0.84%
melanoma nasdaq bell cancer impact skin
TissueCypher® Barrett’s Esophagus Test Outperformed Standard of Care in Risk-Stratifying Patients with Barrett’s Esophagus
Published: 2023-09-14 (Crawled : 13:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: 0.54%
H: 0.89%
C: -5.43%
tissuecypher test care
Castle Biosciences Announces Receipt of New York Laboratory Permit for Pittsburgh Laboratory
Published: 2023-09-12 (Crawled : 12:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: -0.59%
H: 0.92%
C: -2.14%
New Publication Highlights the Ability of the TissueCypher® Barrett’s Esophagus Test to Improve and Standardize the Clinical Management of Low-Grade Dysplasia in Patients with Barrett’s Esophagus
Published: 2023-08-07 (Crawled : 13:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: -1.27%
H: 0.0%
C: 0.0%
tissuecypher management test publication
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.